The estimated Net Worth of Peter Wrighton Smith is at least 16.6 百万$ dollars as of 8 May 2020. Peter Smith owns over 43,600 units of Oxford Immunotec Global PLC stock worth over 8,800,948$ and over the last 11 years he sold OXFD stock worth over 5,626,990$. In addition, he makes 2,151,490$ as Chief Executive Officer、 Director at Oxford Immunotec Global PLC.
Sign up
Peter Smith OXFD stock SEC Form 4 insiders trading
Peter has made over 19 trades of the Oxford Immunotec Global PLC stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 43,600 units of OXFD stock worth 499,656$ on 8 May 2020.
The largest trade he's ever made was selling 100,000 units of Oxford Immunotec Global PLC stock on 23 September 2019 worth over 1,659,000$. On average, Peter trades about 21,734 units every 43 days since 2014. As of 8 May 2020 he still owns at least 400,225 units of Oxford Immunotec Global PLC stock.
You can see the complete history of Peter Smith stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Peter Wrighton-Smith biography
Dr. Peter James Wrighton-Smith serves as Chief Executive Officer, Director of the Company. He has held both positions since founding Oxford Immunotec in 2002. Before founding Oxford Immunotec, Dr. Wrighton-Smith held senior positions with PowderJect Pharmaceuticals PLC, including as managing director of PowderJect Diagnostics Ltd., a subsidiary of PowderJect engaged in the development of cellular immune-based diagnostics. He is presently a member of the Board of Directors of Inivata Limited, a privately held company in clinical cancer genomics. He earned his master’s degree in Engineering, Economics and Management, and his doctorate in Medical Engineering from Oxford University.
What is the salary of Peter Smith?
As the Chief Executive Officer、 Director of Oxford Immunotec Global PLC, the total compensation of Peter Smith at Oxford Immunotec Global PLC is 2,151,490$. There are no executives at Oxford Immunotec Global PLC getting paid more.
How old is Peter Smith?
Peter Smith is 45, he's been the Chief Executive Officer、 Director of Oxford Immunotec Global PLC since 2002. There are 9 older and 1 younger executives at Oxford Immunotec Global PLC. The oldest executive at Oxford Immunotec Global PLC is Richard Sandberg, 77, who is the Independent Director.
What's Peter Smith's mailing address?
Peter's mailing address filed with the SEC is C/O OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, ABINGDON, OXFORDSHIRE, X0, OX14 4RZ.
Insiders trading at Oxford Immunotec Global PLC
Over the last 11 years, insiders at Oxford Immunotec Global PLC have traded over 13,598,906$ worth of Oxford Immunotec Global PLC stock and bought 47,600 units worth 549,576$ . The most active insiders traders include James R Tobin、Peter Wrighton Smith、Ronald Asbury Andrews. On average, Oxford Immunotec Global PLC executives and independent directors trade stock every 36 days with the average trade being worth of 536,006$. The most recent stock trade was executed by Patrick J Balthrop on 20 May 2020, trading 4,000 units of OXFD stock currently worth 49,920$.
What does Oxford Immunotec Global PLC's logo look like?
Complete history of Peter Smith stock trades at Oxford Immunotec Global PLC
Oxford Immunotec Global PLC executives and stock owners
Oxford Immunotec Global PLC executives and other stock owners filed with the SEC include:
-
Peter Wrighton-Smith,
Chief Executive Officer, Director -
Matthew McLaughlin,
Chief Financial Officer -
Richard Sandberg,
Independent Director -
Patrick Balthrop,
Independent Chairman of the Board -
Herman Rosenman,
Independent Director -
James Tobin,
Independent Director -
Patricia Randall,
Independent Director -
Andrew Walton,
Independent Director -
Mark Klausner,
Independent Director -
Ronald Andrews,
Independent Director -
Janet Kidd,
General Counsel, Company Secretary -
Herm Rosenman,
-
Richard M. Altieri,
Chief Financial Officer -
Peter Edwardson,
Chief Operations Officer -
Stephen L Spotts,
Director -
Jeff R. Schroeder,
Chief Commercial Officer -
Richard Wenstrup,
Chief Medical Officer -
Stefan C Linn,
Chief Operating Officer -
Elizabeth M Keiley,
VP & General Counsel -
Lifesciences I, L.P.Clarus ...,
-
Leaf Ventures Ii, L.P.New L...,